The FDA has approved Eli Lilly’s Zepbound for treating obstructive sleep apnea, marking the first drug specifically for this common sleep disorder. Zepbound, containing tirzepatide, a GLP-1 agonist, showed significant effectiveness in clinical trials and could significantly impact the market, given the billions affected by sleep apnea. This approval positions Lilly competitively against other pharmaceutical companies developing similar treatments.